 Connection
Jerry Nick to Cystic Fibrosis
This is a "connection" page, showing publications Jerry Nick has written about Cystic Fibrosis.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
11.651 |
|
|
|
-
Gross JE, Caceres S, Poch K, Epperson LE, Hasan NA, Jia F, Calado Nogueira de Moura V, Strand M, Lipner EM, Honda JR, Strong M, Davidson RM, Daley CL, Nick JA. Prospective healthcare-associated links in transmission of nontuberculous mycobacteria among people with cystic fibrosis (pHALT NTM) study: Rationale and study design. PLoS One. 2023; 18(12):e0291910.
Score: 0.488
-
Gross JE, Teneback CC, Sweet JG, Caceres SM, Poch KR, Hasan NA, Jia F, Epperson LE, Lipner EM, Vang CK, Honda JR, Strand MJ, Calado Nogueira de Moura V, Daley CL, Strong M, Davidson RM, Nick JA. Molecular Epidemiologic Investigation of Mycobacterium intracellulare Subspecies chimaera Lung Infections at an Adult Cystic Fibrosis Program. Ann Am Thorac Soc. 2023 05; 20(5):677-686.
Score: 0.467
-
Lenhart-Pendergrass PM, Malcolm KC, Wheeler E, Rysavy NM, Poch K, Caceres S, Calhoun KM, Martiniano SL, Nick JA. Deficient Complement Opsonization Impairs Mycobacterium avium Killing by Neutrophils in Cystic Fibrosis. Microbiol Spectr. 2023 02 14; 11(1):e0327922.
Score: 0.458
-
Nick JA, Malcolm KC, Hisert KB, Wheeler EA, Rysavy NM, Poch K, Caceres S, Lovell VK, Armantrout E, Saavedra MT, Calhoun K, Chatterjee D, Aboellail I, De P, Martiniano SL, Jia F, Davidson RM. Culture independent markers of nontuberculous mycobacterial (NTM) lung infection and disease in the cystic fibrosis airway. Tuberculosis (Edinb). 2023 01; 138:102276.
Score: 0.453
-
Malcolm KC, Wheeler EA, Calhoun K, Lenhart-Pendergrass PM, Rysavy N, Poch KR, Caceres SM, Saavedra MT, Nick JA. Specificity of Immunoglobulin Response to Nontuberculous Mycobacteria Infection in People with Cystic Fibrosis. Microbiol Spectr. 2022 08 31; 10(4):e0187422.
Score: 0.441
-
Nick JA, Dedrick RM, Gray AL, Vladar EK, Smith BE, Freeman KG, Malcolm KC, Epperson LE, Hasan NA, Hendrix J, Callahan K, Walton K, Vestal B, Wheeler E, Rysavy NM, Poch K, Caceres S, Lovell VK, Hisert KB, de Moura VC, Chatterjee D, De P, Weakly N, Martiniano SL, Lynch DA, Daley CL, Strong M, Jia F, Hatfull GF, Davidson RM. Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection. Cell. 2022 05 26; 185(11):1860-1874.e12.
Score: 0.437
-
Gross JE, Caceres S, Poch K, Hasan NA, Jia F, Epperson LE, Lipner E, Vang C, Honda JR, Strand M, Calado Nogueira de Moura V, Daley CL, Strong M, Davidson RM, Nick JA. Investigating Nontuberculous Mycobacteria Transmission at the Colorado Adult Cystic Fibrosis Program. Am J Respir Crit Care Med. 2022 05 01; 205(9):1064-1074.
Score: 0.436
-
Gross JE, Caceres S, Poch K, Hasan NA, Davidson RM, Epperson LE, Lipner E, Vang C, Honda JR, Strand M, Strong M, Saiman L, Prevots DR, Olivier KN, Nick JA. Healthcare-associated links in transmission of nontuberculous mycobacteria among people with cystic fibrosis (HALT NTM) study: Rationale and study design. PLoS One. 2021; 16(12):e0261628.
Score: 0.425
-
Nick JA, Daley CL, Lenhart-Pendergrass PM, Davidson RM. Nontuberculous mycobacteria in cystic fibrosis. Curr Opin Pulm Med. 2021 11 01; 27(6):586-592.
Score: 0.421
-
Nick JA, St Clair C, Jones MC, Lan L, Higgins M. Ivacaftor in cystic fibrosis with residual function: Lung function results from an N-of-1 study. J Cyst Fibros. 2020 01; 19(1):91-98.
Score: 0.368
-
Gross JE, Martiniano SL, Nick JA. Prevention of transmission of Mycobacterium abscessus among patients with cystic fibrosis. Curr Opin Pulm Med. 2019 11; 25(6):646-653.
Score: 0.367
-
Saavedra MT, Quon BS, Faino A, Caceres SM, Poch KR, Sanders LA, Malcolm KC, Nichols DP, Sagel SD, Taylor-Cousar JL, Leach SM, Strand M, Nick JA. Whole Blood Gene Expression Profiling Predicts Severe Morbidity and Mortality in Cystic Fibrosis: A 5-Year Follow-Up Study. Ann Am Thorac Soc. 2018 05; 15(5):589-598.
Score: 0.330
-
Martiniano SL, Davidson RM, Nick JA. Nontuberculous mycobacteria in cystic fibrosis: Updates and the path forward. Pediatr Pulmonol. 2017 Nov; 52(S48):S29-S36.
Score: 0.316
-
Nichols DP, Happoldt CL, Bratcher PE, Caceres SM, Chmiel JF, Malcolm KC, Saavedra MT, Saiman L, Taylor-Cousar JL, Nick JA. Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis. J Cyst Fibros. 2017 May; 16(3):358-366.
Score: 0.301
-
Taylor-Cousar JL, Janssen JS, Wilson A, Clair CG, Pickard KM, Jones MC, Brayshaw SJ, Chacon CS, Barboa CM, Sontag MK, Accurso FJ, Nichols DP, Saavedra MT, Nick JA. Glucose >200?mg/dL during Continuous Glucose Monitoring Identifies Adult Patients at Risk for Development of Cystic Fibrosis Related Diabetes. J Diabetes Res. 2016; 2016:1527932.
Score: 0.299
-
Nick JA, Pohl K, Martiniano SL. Nontuberculous mycobacterial infections in cystic fibrosis: to treat or not to treat? Curr Opin Pulm Med. 2016 11; 22(6):629-36.
Score: 0.298
-
Nick JA, Nichols DP. Diagnosis of Adult Patients with Cystic Fibrosis. Clin Chest Med. 2016 Mar; 37(1):47-57.
Score: 0.281
-
Nichols DP, Kuk KN, Nick JA. Drug interactions and treatment burden as survival improves. Curr Opin Pulm Med. 2015 Nov; 21(6):617-25.
Score: 0.278
-
Martiniano SL, Nick JA. Nontuberculous mycobacterial infections in cystic fibrosis. Clin Chest Med. 2015 Mar; 36(1):101-15.
Score: 0.265
-
Taylor-Cousar JL, Wiley C, Felton LA, St Clair C, Jones M, Curran-Everett D, Poch K, Nichols DP, Solomon GM, Saavedra MT, Accurso FJ, Nick JA. Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease. J Cyst Fibros. 2015 Mar; 14(2):228-36.
Score: 0.260
-
Nick JA, Moskowitz SM, Chmiel JF, Forss?n AV, Kim SH, Saavedra MT, Saiman L, Taylor-Cousar JL, Nichols DP. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc. 2014 Mar; 11(3):342-50.
Score: 0.247
-
Nick JA, Sanders LA, Ickes B, Briones NJ, Caceres SM, Malcolm KC, Brayshaw SJ, Chacon CS, Barboa CM, Jones MC, St Clair C, Taylor-Cousar JL, Nichols DP, Sagel SD, Strand M, Saavedra MT. Blood mRNA biomarkers for detection of treatment response in acute pulmonary exacerbations of cystic fibrosis. Thorax. 2013 Oct; 68(10):929-37.
Score: 0.236
-
Young RL, Malcolm KC, Kret JE, Caceres SM, Poch KR, Nichols DP, Taylor-Cousar JL, Saavedra MT, Randell SH, Vasil ML, Burns JL, Moskowitz SM, Nick JA. Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR. PLoS One. 2011; 6(9):e23637.
Score: 0.208
-
Nick JA, Chacon CS, Brayshaw SJ, Jones MC, Barboa CM, St Clair CG, Young RL, Nichols DP, Janssen JS, Huitt GA, Iseman MD, Daley CL, Taylor-Cousar JL, Accurso FJ, Saavedra MT, Sontag MK. Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. Am J Respir Crit Care Med. 2010 Sep 01; 182(5):614-26.
Score: 0.190
-
Saavedra MT, Hughes GJ, Sanders LA, Carr M, Rodman DM, Coldren CD, Geraci MW, Sagel SD, Accurso FJ, West J, Nick JA. Circulating RNA transcripts identify therapeutic response in cystic fibrosis lung disease. Am J Respir Crit Care Med. 2008 Nov 01; 178(9):929-38.
Score: 0.169
-
Nick JA, Rodman DM. Manifestations of cystic fibrosis diagnosed in adulthood. Curr Opin Pulm Med. 2005 Nov; 11(6):513-8.
Score: 0.139
-
Hardin DS, Rice J, Cohen RC, Ellis KJ, Nick JA. The metabolic effects of pregnancy in cystic fibrosis. Obstet Gynecol. 2005 Aug; 106(2):367-75.
Score: 0.137
-
Rodman DM, Polis JM, Heltshe SL, Sontag MK, Chacon C, Rodman RV, Brayshaw SJ, Huitt GA, Iseman MD, Saavedra MT, Taussig LM, Wagener JS, Accurso FJ, Nick JA. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med. 2005 Mar 15; 171(6):621-6.
Score: 0.131
-
Martiniano SL, Caceres SM, Poch K, Rysavy NM, Lovell VK, Armantrout E, Jones M, Anthony M, Keck A, Nichols DP, Vandalfsen JM, Sagel SD, Wagner B, Xie J, Weaver K, Heltshe SL, Daley CL, Davidson RM, Nick JA. Prospective evaluation of nontuberculous mycobacteria disease in cystic fibrosis: The design of the PREDICT study. J Cyst Fibros. 2024 Jan; 23(1):50-57.
Score: 0.120
-
Dedrick RM, Smith BE, Cristinziano M, Freeman KG, Jacobs-Sera D, Belessis Y, Whitney Brown A, Cohen KA, Davidson RM, van Duin D, Gainey A, Garcia CB, Robert George CR, Haidar G, Ip W, Iredell J, Khatami A, Little JS, Malmivaara K, McMullan BJ, Michalik DE, Moscatelli A, Nick JA, Tupayachi Ortiz MG, Polenakovik HM, Robinson PD, Skurnik M, Solomon DA, Soothill J, Spencer H, Wark P, Worth A, Schooley RT, Benson CA, Hatfull GF. Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease. Clin Infect Dis. 2023 01 06; 76(1):103-112.
Score: 0.114
-
Martiniano SL, Nick JA, Daley CL. Nontuberculous Mycobacterial Infections in Cystic Fibrosis. Clin Chest Med. 2022 Dec; 43(4):697-716.
Score: 0.113
-
Mani-Varnosfaderani A, Gao A, Poch KR, Caceres SM, Nick JA, Hill JE. Breath biomarkers associated withnontuberculosis mycobacteriadisease status in persons with cystic fibrosis: a pilot study. J Breath Res. 2022 05 13; 16(3).
Score: 0.109
-
Caceres SM, Sanders LA, Rysavy NM, Poch KR, Jones CR, Pickard K, Fingerlin TE, Marcus RA, Malcolm KC, Taylor-Cousar JL, Nichols DP, Nick JA, Strand M, Saavedra MT. Blood mRNA biomarkers distinguish variable systemic and sputum inflammation at treatment initiation of inhaled antibiotics in cystic fibrosis: A prospective non-randomized trial. PLoS One. 2022; 17(5):e0267592.
Score: 0.109
-
Davidson RM, Hasan NA, Epperson LE, Benoit JB, Kammlade SM, Levin AR, Calado de Moura V, Hunkins J, Weakly N, Beagle S, Sagel SD, Martiniano SL, Salfinger M, Daley CL, Nick JA, Strong M. Population Genomics of Mycobacterium abscessus from U.S. Cystic Fibrosis Care Centers. Ann Am Thorac Soc. 2021 12; 18(12):1960-1969.
Score: 0.106
-
Hasan NA, Davidson RM, Epperson LE, Kammlade SM, Beagle S, Levin AR, de Moura VC, Hunkins JJ, Weakly N, Sagel SD, Martiniano SL, Salfinger M, Daley CL, Nick JA, Strong M. Population Genomics and Inference of Mycobacterium avium Complex Clusters in Cystic Fibrosis Care Centers, United States. Emerg Infect Dis. 2021 11; 27(11):2836-2846.
Score: 0.105
-
Nichols DP, Singh PK, Baines A, Caverly LJ, Chmiel JF, GIbson RL, Lascano J, Morgan SJ, Retsch-Bogart G, Saiman L, Sadeghi H, Billings JL, Heltshe SL, Kirby S, Kong A, Nick JA, Mayer-Hamblett N. Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial. Thorax. 2022 06; 77(6):581-588.
Score: 0.105
-
Davidson RM, Benoit JB, Kammlade SM, Hasan NA, Epperson LE, Smith T, Vasireddy S, Brown-Elliott BA, Nick JA, Olivier KN, Zelazny AM, Daley CL, Strong M, Wallace RJ. Genomic characterization of sporadic isolates of the dominant clone of Mycobacterium abscessus subspecies massiliense. Sci Rep. 2021 07 28; 11(1):15336.
Score: 0.103
-
Lipner EM, Crooks JL, French J, Strong M, Nick JA, Prevots DR. Nontuberculous mycobacterial infection and environmental molybdenum in persons with cystic fibrosis: a case-control study in Colorado. J Expo Sci Environ Epidemiol. 2022 03; 32(2):289-294.
Score: 0.103
-
Martiniano SL, Wagner BD, Brennan L, Wempe MF, Anderson PL, Daley CL, Anthony M, Nick JA, Sagel SD. Pharmacokinetics of oral antimycobacterials and dosing guidance for Mycobacterium avium complex treatment in cystic fibrosis. J Cyst Fibros. 2021 09; 20(5):772-778.
Score: 0.102
-
Kazani S, Rowlands DJ, Bottoli I, Milojevic J, Alcantara J, Jones I, Kulmatycki K, Machineni S, Mostovy L, Nicholls I, Nick JA, Rowe SM, Simmonds NJ, Vegesna R, Verheijen J, Danahay H, Gosling M, Ayalavajjala PS, Salman M, Strieter R. Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251). J Cyst Fibros. 2021 03; 20(2):250-256.
Score: 0.099
-
Lenhart-Pendergrass PM, Caverly LJ, Wagner BD, Sagel SD, Nick JA, LiPuma JJ, Martiniano SL. Clinical characteristics and outcomes associated with Inquilinus infection in cystic fibrosis. J Cyst Fibros. 2021 03; 20(2):310-315.
Score: 0.097
-
Pohl K, Grimm XA, Caceres SM, Poch KR, Rysavy N, Saavedra M, Nick JA, Malcolm KC. Mycobacterium abscessus Clearance by Neutrophils Is Independent of Autophagy. Infect Immun. 2020 07 21; 88(8).
Score: 0.096
-
De P, Amin AG, Graham B, Martiniano SL, Caceres SM, Poch KR, Jones MC, Saavedra MT, Malcolm KC, Nick JA, Chatterjee D. Urine lipoarabinomannan as a marker for low-risk of NTM infection in the CF airway. J Cyst Fibros. 2020 09; 19(5):801-807.
Score: 0.096
-
Wiersma CJ, Belardinelli JM, Avanzi C, Angala SK, Everall I, Angala B, Kendall E, de Moura VCN, Verma D, Benoit J, Brown KP, Jones V, Malcolm KC, Strong M, Nick JA, Floto RA, Parkhill J, Ordway DJ, Davidson RM, McNeil MR, Jackson M. Cell Surface Remodeling of Mycobacterium abscessus under Cystic Fibrosis Airway Growth Conditions. ACS Infect Dis. 2020 08 14; 6(8):2143-2154.
Score: 0.096
-
Somayaji R, Russell R, Cogen JD, Goss CH, Nick SE, Saavedra MT, Taylor-Cousar JL, Nick JA, Nichols DP. Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis. Ann Am Thorac Soc. 2019 07; 16(7):853-860.
Score: 0.090
-
Martiniano SL, Nick JA, Daley CL. Nontuberculous Mycobacterial Infections in Cystic Fibrosis. Thorac Surg Clin. 2019 Feb; 29(1):95-108.
Score: 0.087
-
Pohl K, Nichols DP, Taylor-Cousar JL, Saavedra MT, Strand MJ, Nick JA, Bratcher PE. Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation. PLoS One. 2018; 13(12):e0209026.
Score: 0.086
-
Sermet-Gaudelus I, Clancy JP, Nichols DP, Nick JA, De Boeck K, Solomon GM, Mall MA, Bolognese J, Bouisset F, den Hollander W, Paquette-Lamontagne N, Tomkinson N, Henig N, Elborn JS, Rowe SM. Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis. J Cyst Fibros. 2019 07; 18(4):536-542.
Score: 0.086
-
Clancy JP, Cotton CU, Donaldson SH, Solomon GM, VanDevanter DR, Boyle MP, Gentzsch M, Nick JA, Illek B, Wallenburg JC, Sorscher EJ, Amaral MD, Beekman JM, Naren AP, Bridges RJ, Thomas PJ, Cutting G, Rowe S, Durmowicz AG, Mense M, Boeck KD, Skach W, Penland C, Joseloff E, Bihler H, Mahoney J, Borowitz D, Tuggle KL. CFTR modulator theratyping: Current status, gaps and future directions. J Cyst Fibros. 2019 01; 18(1):22-34.
Score: 0.083
-
West NE, Beckett VV, Jain R, Sanders DB, Nick JA, Heltshe SL, Dasenbrook EC, VanDevanter DR, Solomon GM, Goss CH, Flume PA. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations. J Cyst Fibros. 2017 Sep; 16(5):600-606.
Score: 0.077
-
Sanders DB, Solomon GM, Beckett VV, West NE, Daines CL, Heltshe SL, VanDevanter DR, Spahr JE, Gibson RL, Nick JA, Marshall BC, Flume PA, Goss CH. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations. J Cyst Fibros. 2017 Sep; 16(5):592-599.
Score: 0.077
-
Sosnay PR, White TB, Farrell PM, Ren CL, Derichs N, Howenstine MS, Nick JA, De Boeck K. Diagnosis of Cystic Fibrosis in Nonscreened Populations. J Pediatr. 2017 02; 181S:S52-S57.e2.
Score: 0.076
-
Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace RJ, Winthrop KL, Marshall BC, Haworth CS. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax. 2016 Jan; 71 Suppl 1:i1-22.
Score: 0.070
-
Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace RJ, Winthrop KL, Marshall BC, Haworth CS. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. Thorax. 2016 Jan; 71(1):88-90.
Score: 0.070
-
Martiniano SL, Nick JA, Daley CL. Nontuberculous Mycobacterial Infections in Cystic Fibrosis. Clin Chest Med. 2016 Mar; 37(1):83-96.
Score: 0.070
-
Ferril GR, Nick JA, Getz AE, Barham HP, Saavedra MT, Taylor-Cousar JL, Nichols DP, Curran-Everett D, Kingdom TT, Ramakrishnan VR. Comparison of radiographic and clinical characteristics of low-risk and high-risk cystic fibrosis genotypes. Int Forum Allergy Rhinol. 2014 Nov; 4(11):915-20.
Score: 0.064
-
Caceres SM, Malcolm KC, Taylor-Cousar JL, Nichols DP, Saavedra MT, Bratton DL, Moskowitz SM, Burns JL, Nick JA. Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products. Antimicrob Agents Chemother. 2014 Nov; 58(11):6851-60.
Score: 0.064
-
Martiniano SL, Sontag MK, Daley CL, Nick JA, Sagel SD. Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis. Ann Am Thorac Soc. 2014 Jan; 11(1):36-44.
Score: 0.061
-
Walker TS, Tomlin KL, Worthen GS, Poch KR, Lieber JG, Saavedra MT, Fessler MB, Malcolm KC, Vasil ML, Nick JA. Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect Immun. 2005 Jun; 73(6):3693-701.
Score: 0.034
-
Wallick K, Nick JA, Rodman DM. Cystic fibrosis critical care: no longer an oxymoron. Am J Respir Crit Care Med. 2001 Feb; 163(2):310-2.
Score: 0.025
-
Saavedra MT, Patterson AD, West J, Randell SH, Riches DW, Malcolm KC, Cool CD, Nick JA, Dinarello CA. Abrogation of anti-inflammatory transcription factor LKLF in neutrophil-dominated airways. Am J Respir Cell Mol Biol. 2008 Jun; 38(6):679-88.
Score: 0.010
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|